NC
1
Inpharma 1484 - 23 Apr 2005 ■ NC 503 [Fibrillex] * may reduce disease progression in amyloid A amyloidosis, according to preliminary results from the largest placebo-controlled study conducted in patients with this condition to date. This phase II/III study involved 183 patients who received NC 503 (n = 89) or placebo for 24 months. The composite primary endpoint included renal function measurements and mortality; stabilisation or improvement of these measures was achieved in 13.4% more NC 503, compared with placebo, recipients (p = 0.06). * Neurochem, Centocor; phase II/III with orphan drug status for amyloidosis in the US and Europe Neurochem (International) Ltd. Neurochem announces preliminary results of phase II/III clinical study for Fibrillex(TM) - Plans meeting with FDA to present results. Media Release : 18 Apr 2005. Available from: URL: http:// www.neurochem.com 809047946 1 Inpharma 23 Apr 2005 No. 1484 1173-8324/10/1484-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Transcript of NC
Inpharma 1484 - 23 Apr 2005
■ NC 503 [Fibrillex]* may reduce diseaseprogression in amyloid A amyloidosis, according topreliminary results from the largest placebo-controlledstudy conducted in patients with this condition todate. This phase II/III study involved 183 patients whoreceived NC 503 (n = 89) or placebo for 24 months.The composite primary endpoint included renalfunction measurements and mortality; stabilisation orimprovement of these measures was achieved in13.4% more NC 503, compared with placebo,recipients (p = 0.06).* Neurochem, Centocor; phase II/III with orphan drug status foramyloidosis in the US and Europe
Neurochem (International) Ltd. Neurochem announces preliminary results ofphase II/III clinical study for Fibrillex(TM) - Plans meeting with FDA topresent results. Media Release : 18 Apr 2005. Available from: URL: http://www.neurochem.com 809047946
1
Inpharma 23 Apr 2005 No. 14841173-8324/10/1484-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
